ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 970,02
0,40%
Dow Jones
38 711,29
0,36%
DAX
18 518,41
0,55%
Brent Oil
77,73
0,80%
Bitcoin
71 091,98
0,66%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) Actualités

MRUS

Merus NV (MRUS)

Merus NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MRUS
DateHeureSourceTitreSymboleSociété
03/06/202420h30GlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
02/06/202418h30GlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
30/05/202423h21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
30/05/202403h30GlobeNewswire Inc.Merus Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:MRUSMerus NV
29/05/202414h00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:MRUSMerus NV
28/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
28/05/202422h01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
28/05/202413h00GlobeNewswire Inc.Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCNASDAQ:MRUSMerus NV
23/05/202423h00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
13/05/202414h00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
10/05/202422h33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
09/05/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
09/05/202422h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
08/05/202422h15GlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
06/05/202422h05GlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
08/04/202418h00GlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
03/04/202414h00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
06/03/202414h00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:MRUSMerus NV
05/03/202422h30GlobeNewswire Inc.Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionNASDAQ:MRUSMerus NV
04/03/202414h00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma ConferenceNASDAQ:MRUSMerus NV
28/02/202422h55Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:MRUSMerus NV
28/02/202422h15GlobeNewswire Inc.Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
14/02/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRUSMerus NV
31/01/202414h00GlobeNewswire Inc.Merus to Participate in Upcoming Investor ConferencesNASDAQ:MRUSMerus NV
16/12/202301h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
03/12/202302h40GlobeNewswire Inc.Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
26/11/202317h05GlobeNewswire Inc.Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
02/11/202321h12GlobeNewswire Inc.Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/11/202321h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
23/10/202313h30GlobeNewswire Inc.Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerNASDAQ:MRUSMerus NV
 Showing the most relevant articles for your search:NASDAQ:MRUS

Dernières Valeurs Consultées

EU
DG
Vinci
NYSE
JPM
JP Morgan Chase
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
MRK
Merck
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
EU
ACA
Credit Agricole
EU
VIV
Vivendi
EU
PX4
SBF 120
EU
RI
Pernod Ricard
SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
EU
BEL20
Bel 20
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés